Drug intelligence / Profile preview

I123MNI388 + I123MNI390

Development stage: Preclinical
Lead developer: Institute for Neurodegenerative Disorders
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

I123MNI388 + I123MNI390 is a combination of two radiopharmaceutical imaging agents labeled with iodine-123. These compounds are typically used in nuclear medicine for diagnostic imaging, particularly for brain imaging to assess amyloid plaque burden in conditions such as Alzheimer's disease. Both MNI-388 and MNI-390 are small molecules designed to bind specifically to amyloid-beta plaques, and the use of the radioactive isotope iodine-123 allows visualization via single-photon emission computed tomography (SPECT). The combination may be used together to improve sensitivity or specificity of amyloid detection.

Targets

Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on I123MNI388 + I123MNI390.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on I123MNI388 + I123MNI390.

Explore the full profile